Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 17.9% on Wednesday . The stock traded as high as C$0.24 and last traded at C$0.23. 509,888 shares were traded during mid-day trading, a decline of 18% from the average session volume of 624,528 shares. The stock had previously closed at C$0.20.
Hemostemix Price Performance
The company has a market cap of C$19.60 million, a PE ratio of -11.25 and a beta of 0.20. The business’s 50 day moving average is C$0.10 and its 200-day moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Conference Calls and Individual Investors
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- How Do Stock Buybacks Affect Shareholders?
- Are Penny Stocks a Good Fit for Your Portfolio?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
